Cargando…
Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†)
BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The six symptom items' [average symptom burden index (ASBI)] mean at baseline was calculated using...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660084/ https://www.ncbi.nlm.nih.gov/pubmed/23559150 http://dx.doi.org/10.1093/annonc/mdt123 |
_version_ | 1782270504754741248 |
---|---|
author | Obasaju, C. Bowman, L. Wang, P. Shen, W. Winfree, K. B. Smyth, E. N. Boye, M. E. John, W. Brodowicz, T. Belani, C. P. |
author_facet | Obasaju, C. Bowman, L. Wang, P. Shen, W. Winfree, K. B. Smyth, E. N. Boye, M. E. John, W. Brodowicz, T. Belani, C. P. |
author_sort | Obasaju, C. |
collection | PubMed |
description | BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The six symptom items' [average symptom burden index (ASBI)] mean at baseline was calculated using the lung cancer symptom scale (LCSS). Low and high symptom burden (LSB, ASBI < 25; HSB, ASBI ≥ 25) and performance status (PS: 0, 1) subgroups were analyzed for treatment effect on progression-free survival (PFS) and overall survival (OS) using the Cox proportional hazard models adjusted for demographic/clinical factors. RESULTS: Significantly longer PFS and OS for pemetrexed versus placebo occurred in LSB patients [PFS: median 5.1 versus 2.4 months, hazard ratio (HR) 0.49, P < 0.0001; OS: median 17.5 versus 11.0 months, HR 0.63, P = 0.0012] and PS 0 patients (PFS: median 5.5 versus 1.7 months, HR 0.36, P < 0.0001; OS: median 17.7 versus 10.3 months, HR 0.54, P = 0.0019). Significantly longer PFS, but not OS, occurred in HSB patients (median 3.7 versus 2.8 months, HR 0.50, P = 0.0033) and PS 1 patients (median 4.4 versus 2.8 months, HR 0.60, P = 0.0002). CONCLUSIONS: ASBI and PS are associated with survival for non-squamous NSCLC patients, suggesting that maintenance pemetrexed is useful for LSB or PS 0 patients following induction. |
format | Online Article Text |
id | pubmed-3660084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36600842013-05-22 Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) Obasaju, C. Bowman, L. Wang, P. Shen, W. Winfree, K. B. Smyth, E. N. Boye, M. E. John, W. Brodowicz, T. Belani, C. P. Ann Oncol Original Articles BACKGROUND: This was a post hoc analysis of patients with non-squamous histology from a phase III maintenance pemetrexed study in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The six symptom items' [average symptom burden index (ASBI)] mean at baseline was calculated using the lung cancer symptom scale (LCSS). Low and high symptom burden (LSB, ASBI < 25; HSB, ASBI ≥ 25) and performance status (PS: 0, 1) subgroups were analyzed for treatment effect on progression-free survival (PFS) and overall survival (OS) using the Cox proportional hazard models adjusted for demographic/clinical factors. RESULTS: Significantly longer PFS and OS for pemetrexed versus placebo occurred in LSB patients [PFS: median 5.1 versus 2.4 months, hazard ratio (HR) 0.49, P < 0.0001; OS: median 17.5 versus 11.0 months, HR 0.63, P = 0.0012] and PS 0 patients (PFS: median 5.5 versus 1.7 months, HR 0.36, P < 0.0001; OS: median 17.7 versus 10.3 months, HR 0.54, P = 0.0019). Significantly longer PFS, but not OS, occurred in HSB patients (median 3.7 versus 2.8 months, HR 0.50, P = 0.0033) and PS 1 patients (median 4.4 versus 2.8 months, HR 0.60, P = 0.0002). CONCLUSIONS: ASBI and PS are associated with survival for non-squamous NSCLC patients, suggesting that maintenance pemetrexed is useful for LSB or PS 0 patients following induction. Oxford University Press 2013-06 2013-04-04 /pmc/articles/PMC3660084/ /pubmed/23559150 http://dx.doi.org/10.1093/annonc/mdt123 Text en © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Obasaju, C. Bowman, L. Wang, P. Shen, W. Winfree, K. B. Smyth, E. N. Boye, M. E. John, W. Brodowicz, T. Belani, C. P. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title_full | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title_fullStr | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title_full_unstemmed | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title_short | Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†) |
title_sort | identifying the target nsclc patient for maintenance therapy: an analysis from a placebo-controlled, phase iii trial of maintenance pemetrexed (h3e-mc-jmen)(†) |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660084/ https://www.ncbi.nlm.nih.gov/pubmed/23559150 http://dx.doi.org/10.1093/annonc/mdt123 |
work_keys_str_mv | AT obasajuc identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT bowmanl identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT wangp identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT shenw identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT winfreekb identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT smythen identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT boyeme identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT johnw identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT brodowiczt identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen AT belanicp identifyingthetargetnsclcpatientformaintenancetherapyananalysisfromaplacebocontrolledphaseiiitrialofmaintenancepemetrexedh3emcjmen |